Algorithm for selection of antihypertensive treatment in patients with metabolic syndrome and hypertension
https://doi.org/10.21518/2079-701X-2013-9-56-64
Abstract
Algorithm for selection of antihypertensive treatment in patients with metabolic syndrome and hypertension ACE inhibitors and angiotensin II receptor blockers are major antihypertensive classes of drugs used in the treatment of hypertension in patients with metabolic syndrome. Each drug in the group is characterized by specific clinical and pharmacological features and application patterns. An algorithm for differential choice of drugs is suggested based on the review of their peculiarities.
About the Authors
S. V. Nedogoda
Volgograd State Medical University
Russian Federation
Russian Federation
T. A. Chalyabi
Volgograd State Medical University
Russian Federation
Russian Federation
A. S. Salasyuk
Volgograd State Medical University
Russian Federation
Russian Federation
I. N. Barykina
Volgograd State Medical University
Russian Federation
Russian Federation
D. A. Pocheptsov
Volgograd State Medical University
Russian Federation
Russian Federation
A. A. Ledyaeva
Volgograd State Medical University
Russian Federation
Russian Federation
V. V. Tsoma
Volgograd State Medical University
Russian Federation
Russian Federation
E. V. Chumachek
Volgograd State Medical University
Russian Federation
Russian Federation
References
1. ESH/ESC Guidelines for the management of arterial hypertension . Journal of Hypertension 2013; 31:1281–1357.
2. Elliott W., Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2010; 369: 201 – 207.
3. Krysiak1 R., Sierant1 M.., et al. The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Pol J Endocrinol 2010; 61 (3): 280–286
4. Krysiak1 R., Sierant1 M.., et al. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Pol J Endocrinol 2010; 61 (6): 683–690
5. Nedogoda S., Ledyaeva A.,Chumachok E., Tsoma V., Mazina G., Salasyuk A., Barykina I. Randomized Trial of Perindopril, Enalapril, Losartan And Telmisartan in Overweight or Obese Patients With Hypertension // Clin Drug Investig 2013, 33:553–561
6. Vitale С., Mercuro G., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology 2005; 4:6-11.
7. Лебедева М.В., Стахова Т.Ю., Минакова Е.Г., Зайцева Л.И., Северова М.М., Пулин А.А. Функция эндотелия у больных с артериальной гипертензией и нарушением обмена мочевой кислоты // Вестник Российской АМН. 2010. №12. С. 44-46.
8. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мальто А.С. Мочевая кислота – ключевой компонент кардиоренометаболического континуума // Кардиоваскулярная терапия и профилактика 2008. №4.95-106.
9. Alderman M., Aiyer K.J. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369–379.
10. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 366:1477-90.
11. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003;2:29-34.
12. Fogari R., Preti P., Derosa G. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002;58(3):177-80.
13. Lindholm L.H., Persson M., Alaupovic P., Carlberg B. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertension 2003;21(8):1563-1574.
14. Мамирбаева К.М., Мычка В.Б., Сергиенко В.Б., Чазова И.Е. Метаболический синдром и антагонисты рецепторов ангиотензина II. // Кардиоваскулярная терапия и профилактика 2007. №2. С.42-51.
15. Kintscher U., Bramlage P., et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovascular Diabetology 2007; 6: 12-16.
16. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43(5):993-1002
17. Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013,7(3):229-35
18. Derosa G., Fogari D., et al. Metabolic effects of telmisartan and irbesartan in type 2diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of Clinical Pharmacy and Therapeutics 2007; 32: 261–268.
19. Rizos CV, Milionis HJ, Kostapanos MS, et al. Effects of rosuvastatin combi-ned with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospectivestudy. Clin Ther 2010; 32:492-505.
Review
For citations:
Nedogoda SV, Chalyabi TA, Salasyuk AS, Barykina IN, Pocheptsov DA, Ledyaeva AA, Tsoma VV, Chumachek EV. Algorithm for selection of antihypertensive treatment in patients with metabolic syndrome and hypertension. Meditsinskiy sovet = Medical Council. 2013;(9):56-64. (In Russ.) https://doi.org/10.21518/2079-701X-2013-9-56-64
Views:
745
Email this article 